Lynch Regenerative Medicine develops biotherapeutics by leveraging extensive research into platelet-derived growth factor (PDGF). The company offers FDA-approved medications and topical aesthetics products that utilize PDGF to promote tissue regeneration and wound healing. Their focus is on translating PDGF science into effective therapeutic and cosmetic applications.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The current market for skin rejuvenation and wound healing lacks consistent and effective solutions, particularly for chronic and acute wounds and aesthetic applications. Existing treatments may not fully leverage the body's natural regenerative capabilities, leading to suboptimal outcomes and prolonged healing times.
Solution
Lynch Regenerative Medicine addresses these needs by developing and commercializing regenerative medicine products based on recombinant human platelet-derived growth factor (rhPDGF). Their portfolio includes REGRANEX® Gel, an FDA-approved treatment for diabetic neuropathic ulcers, and ariessence pure PDGF+, a topical solution for skin rejuvenation. The company's proprietary technology harnesses the power of PDGF to attract stem cells and promote tissue regeneration in both aesthetic and wound-healing applications. By utilizing a pure and potent form of rhPDGF, Lynch Regenerative Medicine aims to provide clinicians with reliable and effective tools to accelerate healing, improve skin health, and address a wide range of skin conditions.
Target Audience
The primary target audience includes wound care clinics, hospitals, podiatrists for wound healing applications, and aesthetic providers for skin rejuvenation treatments.
Features
- REGRANEX® Gel: FDA-approved for the treatment of lower extremity diabetic neuropathic ulcers extending into the subcutaneous tissue.
- ariessence pure PDGF+: A topical solution designed for skin rejuvenation post-procedure.
- Utilizes recombinant human platelet-derived growth factor (rhPDGF) to stimulate stem cell activity and tissue regeneration.
- Products are based on technology with over 100 clinical trials and 1000 published papers.
- rhPDGF is produced using recombinant technology, ensuring a consistent and potent product.